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1BAcKgrouNd
The safety concerns around the misuse of non-prescription medicinal 
products containing codeine are well established. Consumption of quantities 
of these medicines in excess of the recommended dose, or over a prolonged 
period of time, may cause tolerance and dependence, as well as the risk of 
other adverse effects. Furthermore, the consumption of excessive quantities 
of ‘combination products’, i.e. those containing codeine and another 
analgesic such as paracetamol, aspirin or ibuprofen, also increases the risk 
of harm from these other medicinal products. This risk applies to both short 
and long-term use.
Recent publications have highlighted the ongoing concerns regarding these 
medicinal products in other jurisdictions. This includes publications by the 
UK’s Medicines and Healthcare products Regulatory Authority (MHRA), the 
Pharmaceutical Society of Northern Ireland (PSNI), the Royal Pharmaceutical 
Society of Great Britain (RPSGB), the Therapeutic Goods Administration 
(TGA) in Australia and pharmacy regulatory authorities in Canada.
This guidance aims to ensure the safe supply of these medicinal products 
and to assist pharmacists in discharging their legal and professional 
obligations to patients seeking advice, guidance and assistance in respect of 
the use of these medicinal products. The guidance includes the following key 
points: 
•	 Non-prescription ‘combination’ products, containing codeine and 
paracetamol, aspirin or ibuprofen, should be supplied only when the 
pharmacist	is	satisfied	that,	in	the	exercise	of	his	or	her	professional	
judgement, the supply of such a medicine is the most appropriate therapy 
available at the time and that such supply is in the best interest of the 
patient. For pain relief, single ingredient medicinal products such as 
paracetamol,	aspirin	or	ibuprofen,	should	be	used	first	in	line	with	pain	
protocols and current evidence-based practice. Codeine-containing medicinal 
products should be supplied as ‘second line’ products for the treatment of 
pain relief, when the above products have not shown to be effective. 
•	 Every time a non-prescription medicinal product containing codeine 
is supplied, the patient needs to be fully advised of the correct use of the 
product and the risks associated with its misuse. It is also essential that 
patients be facilitated and encouraged to obtain medical assistance for any 
health problems related to their misuse that may arise. 
• Non-prescription medicinal products containing codeine should only 
be supplied and used in accordance with the terms of their marketing 
authorisations, which all state that the product be used for short-term use, 
i.e. no longer than three days. 
• According to current legislative requirements, these products should 
not be accessible to the public for self-selection and therefore, in a retail 
pharmacy business (pharmacy), non-prescription medicinal products 
containing codeine should be stored in an area under the direct control of the 
pharmacist and out of the view of the public.
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This guidance sets out the criteria to be adhered to by pharmacists, 
with a view to ensuring the safe supply of non-prescription medicinal 
products containing codeine (hereafter called ‘codeine medicines’) to 
patients. It is intended to assist pharmacists in meeting their professional 
and legal responsibilities in the supply of these medicines, and to assist 
superintendent and supervising pharmacists in securing compliance with 
relevant legislative and professional obligations under the Pharmacy Act 
2007, including the Regulation of Retail Pharmacy Businesses Regulations 
2008 (S.I. No. 488 of 2008). The overall purpose of this guidance is to 
improve patient safety in the use of these medicines.
Codeine phosphate is a mild to moderate opioid (narcotic) analgesic and has 
weak cough suppressant activity.1 Codeine, due to its potential for misuse, 
is a controlled drug under the Misuse of Drugs Acts 1977 and 1984. Low 
dose preparations are regulated as a Schedule 5 controlled drug. As an 
analgesic, it is most often used in combination with other analgesics such as 
paracetamol or ibuprofen and is currently authorised in Ireland in such non-
prescription products for pain relief. It is also available in single ingredient, 
non-prescription products, as a cough suppressant. These authorised 
products are available without a prescription through retail pharmacy 
businesses only. 
 
The Pharmacy Act 2007 and the Regulation of Retail Pharmacy Businesses 
Regulations 2008 (S.I. No. 488 of 2008) require that all medicines supplied 
through a retail pharmacy business must be supplied by or under the 
personal supervision of a pharmacist (regulation 5(1)(d)) and that all 
non-prescription medicines supplied must be the subject of appropriate 
counselling (regulation 10). In addition, because of the particular 
characteristics of those medicines containing controlled drugs (i.e. codeine), 
further restrictions are imposed which require that those medicinal products 
would not be accessible to the public for self-selection (regulation 5(1)
(e)). Therefore, self-selection of medicinal products containing controlled 
drugs (i.e. CD5 medicines) without the provision of appropriate supervision, 
professional support, advice and information by the pharmacist is not 
appropriate.       
Codeine medicines should only be supplied when the pharmacist deems 
such a supply is necessary and only when a non-opioid analgesic, e.g. 
paracetamol	aspirin	or	ibuprofen,	has	not	proven	sufficient	to	relieve	the	
patient’s symptoms. If recommended, codeine medicines should be used for 
the shortest time possible and for no longer than three days without medical 
supervision. 
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Codeine is a narcotic analgesic and it is important that the recommended 
dose should not be exceeded in any 24-hour period. Consumption of 
quantities in excess of the recommended dose, or consumption over a 
prolonged period of time, may cause tolerance and dependence and may 
result in withdrawal symptoms such as restlessness and irritability upon 
cessation of the medicine.1 If a patient needs to use codeine medicines for 
periods longer than the three days, it is considered important that they 
consult their doctor to investigate unresolved symptoms and the most 
appropriate treatment.
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regulation of retail Pharmacy Businesses regulations 2008  
(s.i. No. 488 of 2008)2
These regulations set out the requirements that must be complied with 
by persons carrying on retail pharmacy businesses in their dealings with 
medicinal products. 
 
Management and supervision of a retail pharmacy business
 
According to the Regulation of Retail Pharmacy Businesses Regulations 2008 
(S.I. No. 488 of 2008) the sale and supply of all medicinal products must be 
by or under the personal supervision of pharmacist.
 
Regulation 5(1)(d): the sale or supply of medicinal products, including 
veterinary medicinal products, and the preparation, dispensing and 
compounding of prescriptions, including veterinary prescriptions, at 
the premises, are carried out by or under the personal supervision of a 
registered pharmacist,
 
Furthermore, Regulation 5(1)(e) of those Regulations requires that any 
medicinal product which is a Schedule 5 controlled drug (non-prescription 
medicinal products containing codeine) must not be accessible to the public 
for self-selection.
Regulation 5(1)(e): medicinal products that are subject to prescription 
control under the Medicinal Products (Prescription and Control of Supply) 
Regulations 2003 (S.I. No. 540 of 2003) (as amended) and medicinal  
products that are controlled drugs listed in Schedule 5 to the Misuse of 
Drugs Regulations 1988 (S.I. No. 328 of 1988) (as amended) are not 
accessible to the public for self-selection,
 
 
code of conduct for Pharmacists
The	first	principle	of	the	Code	of	Conduct	for	pharmacists	requires	that	the	
practice by a pharmacist of his/her profession must be directed toward 
maintaining and improving the health, wellbeing, care and safety of 
patients. Pharmacists should use their professional skills and competence, 
and specialised knowledge, to encourage the rational and proper use of 
medicines. They may be required to use their professional skills in decision-
making,	which	may	at	times	come	into	conflict	with	the	demands	of	the	
patient. 
 
Pharmacists, in particular superintendent and supervising pharmacists, 
should ensure that, in whichever areas of practice they operate, suitable 
controls and accountability mechanisms are in place, in order to 
appropriately control the supply of all medicinal products which are known 
to have the potential for abuse and/or dependency.
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Counselling in the supply of medicinal products other than on foot of 
a prescription
Regulation 10 of those Regulations, in particular, sets out the role and 
responsibility of pharmacists in the sale and supply of non-prescription 
medicines. 
 
Regulation 10: A person carrying on a retail pharmacy business, the 
superintendent pharmacist and the supervising pharmacist shall ensure 
that, in the course of the sale or supply of a medicinal product other than 
on foot of a prescription and prior to such sale or supply, a registered 
pharmacist is satisfied that the purchaser or other such person is aware 
of what the appropriate use of the medicinal product is and that it is being 
sought for that purpose and, in so far as the registered pharmacist is aware, 
the product is not intended for abuse and/or misuse.
Medicinal Products (control of Advertising) regulations 2007 (s.i. 
No. 541 of 2007)
 
Regulation 10 of these Regulations, in relation to advertising directed wholly 
or mainly at members of the general public, provides that: “a person shall 
not issue an advertisementi  in respect of any medicinal product which is a 
controlled drug under section 2 of the Misuse of Drugs Act 1977 (No. 12 of 
1977)”.
In addition, Regulation 22(2) of those Regulations provides that: “a person 
shall not supply a sample of a medicinal product which is a controlled 
drug under section 2 of the Misuse of Drugs Act 1977 or which is an 
antidepressant, hypnotic, sedative or tranquilliser”.
As a consequence of these provisions any form of advertising of a medicinal 
product that is a controlled drug, irrespective of the schedule into which 
the	drug	is	classified,	that	is	directed	at	the	public	is	prohibited.	This	
would include any form of window displays, in-pharmacy promotions and 
promotional	displays,	promotional	leaflets	and	shelf	stickers.
 i ‘advertising’, in relation to a medicinal product, includes any form of door to door information, canvassing activity or inducement designed 
to promote the prescription, supply, sale or consumption of medicinal products and including in particular— 
(a) the advertising of medicinal products to the general public; 
(b) the advertising of medicinal products to persons qualified to prescribe or supply them;
(c) visits by medical sales representatives to persons qualified to prescribe medicinal products;
(d) the supply of samples of medicinal products;
(e) the provision of inducements to prescribe or supply medicinal products by the gift, offer or promise of any benefit or bonus, whether in 
money or in kind;
(f) the sponsorship of promotional meetings attended by persons qualified to prescribe or supply medicinal products; and
(g) the sponsorship of scientific congresses attended by persons qualified to prescribe or supply medicinal products and in particular 
payment of their travelling and accommodation expenses in connection therewith;and cognate words shall be construed accordingly;
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1. supply of medicines containing codeine by a pharmacist from a 
retail pharmacy business
(a) Codeine medicines are currently authorised for the relief of pain in 
conditions such as rheumatic and muscular pain, migraine, headache, 
menstrual pain, toothache, backache and for symptoms of the common 
cold	and	influenza,	and	the	majority	are	available	as	non-prescription	
medicines from retail pharmacy businesses only.3
(b) The supply of codeine medicines may only be made by or under 
the personal supervision of a pharmacist who would be in a position to 
determine the appropriateness of the request for and the supply of these 
medicines. In addition, because of the particular characteristics of those 
medicines containing controlled drugs (i.e. codeine), further restrictions 
are imposed which require that those products would not be accessible 
to the public for self-selection.
(c) Every time a codeine medicine is supplied the pharmacist must be 
satisfied	that,	in	the	exercise	of	his	or	her	professional	judgement,	the	
supply of such a medicine is the most appropriate treatment available 
at the time and that such supply is in the best interest of the patient. It 
should also be taken into account that non-codeine-containing medicinal 
products	for	the	same	indications	should	be	considered	as	first-line	
treatments, e.g. ibuprofen, paracetamol or aspirin.4
(d) The	pharmacist	is	often	the	first	point	of	contact	for	a	patient	and	
therefore has an important role to discharge in the correct management 
of pain. This includes providing appropriate advice or medication, 
recognising the need for referral for further medical investigation and 
the need for vigilance in relation to the presentation of patients with 
medication overuse headache and chronic daily headache. 
(e) Codeine medicines should only be taken when the pharmacist 
considers it necessary and for the shortest period considered necessary. 
Combination products with ibuprofen and paracetamol recommend that 
the duration of treatment should be for no longer than three days. Any 
requirement for more prolonged use should only be considered under 
medical supervision.
(f) Patients should be advised of the importance of adhering to the 
recommended dosage and duration of use. Patients should be informed 
that chronic use and consumption of quantities in excess of the 
recommended dose, or for a prolonged period of time, may lead to 
tolerance, psychological and physical dependence and may result in the 
development of symptoms such as restlessness and irritability upon 
cessation of this medicine.1
6 7
(g) The risks associated with overdose and/or prolonged use should be 
addressed with the patient.
(h) For products which also contain paracetamol or ibuprofen, the 
patient should be informed that these medicines have the potential to be 
harmful in overdose quantities or if used for a prolonged period of time.
(i) If patients experience the need to use codeine medicines over a 
prolonged period of time (i.e. more than three days) for pain relief or 
relief of another symptom, the patient should be referred to a medical 
practitioner who would be able to review their symptoms and provide 
appropriate treatment under medical supervision.
(j) Patients should also be counselled in the course of each supply in 
respect of other potential adverse reactions or side effects, including 
nausea,	constipation,	dizziness	and	drowsiness	(which	may	impair	their	
ability to drive safely). They should also be counselled, as appropriate, 
regarding the contraindications for use, drug interactions, or existing 
medical conditions which may preclude the use of these medicines. The 
need for safe storage of these medicines should also be addressed with 
patients.
82. Appropriate policies and procedures within a retail pharmacy 
business (pharmacy)  
Superintendent pharmacists must ensure that the policies in the retail 
pharmacy business(es) under their control adhere to this guidance and 
the associated legislative requirements. They and their supervising 
pharmacists must ensure that there are adequate procedures in place in 
the retail pharmacy business(es) to ensure compliance with all of these 
policies.
 
(a) The pharmacist should ensure that suitable controls and 
accountability mechanisms are in place to govern the management 
of the supply and distribution of medicinal products which have the 
potential for abuse or dependency.
(b) A	pharmacy-specific	policy	addressing	the	supply	of	medicines	
containing	codeine	should	be	developed,	with	specific	patient	
consultation protocols included. All pharmacy staff should be familiar 
with these policies and should be trained in associated procedures.
(c) In any retail pharmacy business supplying codeine medicines, it is 
the responsibility of the superintendent pharmacist to ensure there is 
a policy in place to manage such supply. It is the responsibility of the 
supervising pharmacist to develop, maintain and ensure adherence to 
this policy and it is the responsibility of each pharmacist to ensure they 
and their staff fully comply with its provisions.
(d) These policies and procedures should take account of the current 
legislative requirements and the guidance criteria included in this 
document.
3. Management and supervision of the accessibility of codeine 
medicines (cd5 medicines) in retail pharmacy businesses
(a) According to the Regulation of Retail Pharmacy Businesses 
Regulations 2008 (S.I. No. 488 of 2008), any medicinal product 
containing a prescription-only medicine or a CD5 medicine must 
not be accessible to the public for self-selection.2 Therefore codeine 
medicines must be in an area of the retail pharmacy business under the 
pharmacist’s direct management and supervision, out of the sight of 
the public. The recommended location is in the dispensary unless, for 
justifiable	reasons,	e.g.	a	shortage	of	storage	space,	an	alternative	out-
of-sight location within the pharmacy is used. This area must be close to 
the dispensary and therefore under the pharmacist’s direct supervision.
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5. Pharmacovigilance
(a)   As with all medicines, any suspected adverse reaction should be 
reported to the Irish Medicines Board (IMB), preferably online, via the 
IMB website www.imb.ie
4. suspected abuse and/or misuse
(a) If a pharmacist becomes aware of a suspected abuse/misuse/
addiction	issue	regarding	a	specific	patient	and	directly	associated	
with the use of codeine medicines, they should make all reasonable 
attempts to ensure that the patient is facilitated and encouraged in 
accessing services which will assist in the management of that addiction. 
The	patient	should	be	referred	in	the	first	instance	to	their	general	
practitioner or an addiction outreach worker, if available in the area. 
Further information on the available services can be obtained from the 
HSE website, www.hse.ie.
 
(b) The policy and procedures documentation in the retail pharmacy 
business should include contact details for the national and/or local 
support and treatment services which are available to patients.
(c) In order to ascertain whether abuse and/or misuse is occurring, 
pharmacists will need to monitor or audit the sale and supply of these 
medicines on an ongoing basis. The management of any data or 
information recorded, collected or retained as part of this monitoring 
or audit should be in accordance with relevant legislative provisions, 
including those of the Data Protection Acts 1988 and 2003.
6. Advertising of codeine medicines
(a) The advertising of codeine medicines is prohibited.  This would 
include any form of window displays, in-pharmacy promotions and 
promotional	displays,	promotional	leaflets	and	shelf	stickers.
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